Just last month, BeiGene received FDA approval for tislelizumab (Tevimbra) as a second-line monotherapy for the treatment of adult patients
Tislelizumab Treatment of Hepatocellular Carcinoma Designated Not FDA Approved for Orphan Indication.
Approval FDA Approves Tevimbra (tislelizumab-jsgr) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma: : BeiGene s Biologics License Application for Tevimbra (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA:
The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of
The FDA has approved a new infused therapy, Tevimbra (tislelizumab-jsgr) from BiGene, indicated for the treatment of adult patients with unresectable or
Shaye Zyskowski's Post FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy Explore topics.
tislelizumab in participants With Advanced or Metastatic FDA Approvals and Expanding Indications Improved Diagnostic Tools
Ma - BeiGene announced the FDA approval of Tevimbra (tislelizumab-jsgr), as a single agent, for the treatment of adult patients
Data from the phase 3 RATIONALE 302 trial (NCT ) supported the FDA approval of tislelizumab-jsgr as a treatment for those with
Comments
What the hell would the FDA have to do with it? This is a piece of machinery. They would have NO say about it whatsoever.
Good story - would like to see more!
Do you realize the world doesn't end at USA borders?